c.US$2m multiplex diagnostic test contract win Development, scale-up and technical transfer for a semi-quantitative, multiplex lateral flow test system
Abingdon Health plc (AIM: ABDX) Trading update
Revenue for FY25 in line with market expectations of £8.6m Continued strong revenue growth anticipated in FY26
Abingdon Health plc (AIM: ABDX) c. US$2.5m companion diagnostic test contract win
c. US$2.5m companion diagnostic test contract win Full CDMO service contract for development, scale-up, technical transfer, manufacture and full regulatory support
Fusion Antibodies (AIM:FAB) Contract win
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has been selected to proceed with a new stable
Fusion Antibodies (AIM:FAB) OptiMAL R&D Update
OptiMAL® R&D Update
Abingdon Health PLC (AIM:ABDX) Funding award to develop test for malaria parasite
Point-of-care rapid diagnostic test for Plasmodium vivax infection to be developed for in-field testing
Abingdon Health PLC (AIM:ABDX) Appointment of Chief Financial Officer
York, U.K. 19 December 2024: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), announces the appointment of Tom Hayes as
Abingdon Health plc (AIM:ABDX) Contract win worth up to US$2million across 2025
Contract win: sexually transmitted disease tests Regulatory and clinical trials contract worth up to US$2million across 2025
Abingdon Health PLC (AIM: ABDX) Opening of US commercial office and laboratory
Abingdon Health plc (AIM: ABDX), a leading international medical device contract development and manufacturing organisation (CDMO), announces it has signed a lease to open a commercial office and laboratory in Madison,
Abingdon Health PLC (AIM: ABDX) Results of the Retail Offer
Completion of Retail Offer
Abingdon Health PLC (AIM:ABDX) Annual Revenue Growth of 52%, Cashflow Positive in Q4
The board anticipates continued solid revenue growth in FY 2025
Abingdon Health PLC (AIM:ABDX) Design freeze completion & strategic partnership
Four sexually transmitted disease lateral flow self-tests complete design freeze.